BR0210261A - Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes - Google Patents
Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destesInfo
- Publication number
- BR0210261A BR0210261A BR0210261-7A BR0210261A BR0210261A BR 0210261 A BR0210261 A BR 0210261A BR 0210261 A BR0210261 A BR 0210261A BR 0210261 A BR0210261 A BR 0210261A
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- apomorphine
- prodrugs
- pharmaceutical formulations
- efficient administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"FORMULAçõES FARMACêUTICAS PARA A ADMINISTRAçãO EFICIENTE DE APOMORFINA, 6aR-(-)-N-PROPIL-NORAPOMORFINA E SEUS DERIVADOS E PRó-DROGAS DESTES". A presente invenção refere-se a uma formulação farmacêutica para o tratamento de uma doença selecionada do grupo consistindo em doença de Parkinson, síndrome das pernas inquietas, disfunção erétil masculina e disfunção sexual feminina. A composição compreende, pelo menos um membro selecionado dentre o grupo consistindo em apomorfina, 6aR-(-)-N-propil-norapomorfina e seus derivados e suas pró-drogas na forma de base, ou de sal farmaceuticamente aceitável ou solvatos destes, como um ingrediente ativo em uma preparação farmacêutica adequada para administração oral/intraduodenal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102036A SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
PCT/SE2002/001106 WO2002100377A1 (en) | 2001-06-08 | 2002-06-07 | PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0210261A true BR0210261A (pt) | 2004-07-20 |
Family
ID=20284413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210261-7A BR0210261A (pt) | 2001-06-08 | 2002-06-07 | Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes |
Country Status (19)
Country | Link |
---|---|
US (2) | US20040220205A1 (pt) |
EP (1) | EP1401398A1 (pt) |
JP (1) | JP2005508865A (pt) |
KR (2) | KR20040007644A (pt) |
CN (1) | CN1286451C (pt) |
AU (1) | AU2002309429B2 (pt) |
BR (1) | BR0210261A (pt) |
CA (1) | CA2449571A1 (pt) |
CZ (1) | CZ20033332A3 (pt) |
EA (1) | EA008409B1 (pt) |
HU (1) | HUP0400200A3 (pt) |
IL (1) | IL158898A0 (pt) |
MX (1) | MXPA03011314A (pt) |
NO (1) | NO20035438L (pt) |
NZ (1) | NZ529623A (pt) |
PL (1) | PL367883A1 (pt) |
SE (1) | SE0102036D0 (pt) |
WO (1) | WO2002100377A1 (pt) |
ZA (1) | ZA200309048B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
CA2529528A1 (en) | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
TWI404702B (zh) | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
US8129530B2 (en) | 2007-08-31 | 2012-03-06 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
US8592424B2 (en) * | 2008-06-30 | 2013-11-26 | Afgin Pharma Llc | Topical regional neuro-affective therapy |
EP2401255A1 (en) | 2009-02-25 | 2012-01-04 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
ES2699077T3 (es) | 2009-06-12 | 2019-02-07 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
NZ612686A (en) | 2010-12-16 | 2015-11-27 | Cynapsus Therapeutics Inc | Sublingual films |
KR101374500B1 (ko) * | 2012-10-09 | 2014-03-13 | 울산대학교 산학협력단 | R(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
WO2016103262A2 (en) * | 2014-12-23 | 2016-06-30 | Neuroderm Ltd | Crystal forms of apomorphine and uses thereof |
US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
BR112017018944A2 (pt) | 2015-03-02 | 2018-05-15 | Afgin Pharma Llc | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) |
EP3285771A4 (en) | 2015-04-21 | 2018-12-05 | Sunovion Pharmaceuticals Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
US20180280465A1 (en) | 2015-09-28 | 2018-10-04 | Ever Neuro Pharma Gmbh | Aqueous composition of apomorphine for subcutaneous administration |
US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
US10729710B2 (en) | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
EP3972971A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
US20220220077A1 (en) | 2019-05-21 | 2022-07-14 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
JP2022533914A (ja) | 2019-05-21 | 2022-07-27 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ |
US20220213071A1 (en) | 2019-05-21 | 2022-07-07 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
CN116568672A (zh) | 2020-11-17 | 2023-08-08 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
WO2023242355A1 (en) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4080456A (en) * | 1971-10-26 | 1978-03-21 | Schering Aktiengesellschaft | Diacylapomorphines |
DE2717001C2 (de) * | 1977-04-18 | 1984-06-20 | Karl O. Helm Ag, 2000 Hamburg | Arzneimittel mit antithrombotischer Wirkung |
US4120860A (en) * | 1977-05-10 | 1978-10-17 | Cooper Lab | 3-Aryl-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds |
DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
US5222236A (en) * | 1988-04-29 | 1993-06-22 | Overdrive Systems, Inc. | Multiple integrated document assembly data processing system |
CA2013485C (en) * | 1990-03-06 | 1997-04-22 | John Michael Gardlik | Solid consumer product compositions containing small particle cyclodextrin complexes |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
CZ20023637A3 (cs) * | 2000-04-07 | 2003-02-12 | Tap Pharmaceutical Products, Inc. | Deriváty apomorfinu a způsoby jejich použití |
SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
US7238702B2 (en) * | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
-
2001
- 2001-06-08 SE SE0102036A patent/SE0102036D0/xx unknown
-
2002
- 2002-06-07 IL IL15889802A patent/IL158898A0/xx unknown
- 2002-06-07 KR KR10-2003-7015814A patent/KR20040007644A/ko not_active Application Discontinuation
- 2002-06-07 EA EA200400007A patent/EA008409B1/ru not_active IP Right Cessation
- 2002-06-07 JP JP2003503201A patent/JP2005508865A/ja not_active Withdrawn
- 2002-06-07 EP EP02736413A patent/EP1401398A1/en not_active Withdrawn
- 2002-06-07 HU HU0400200A patent/HUP0400200A3/hu unknown
- 2002-06-07 CA CA002449571A patent/CA2449571A1/en not_active Abandoned
- 2002-06-07 CN CNB028114760A patent/CN1286451C/zh not_active Expired - Fee Related
- 2002-06-07 CZ CZ20033332A patent/CZ20033332A3/cs unknown
- 2002-06-07 MX MXPA03011314A patent/MXPA03011314A/es not_active Application Discontinuation
- 2002-06-07 NZ NZ529623A patent/NZ529623A/en unknown
- 2002-06-07 US US10/478,692 patent/US20040220205A1/en not_active Abandoned
- 2002-06-07 WO PCT/SE2002/001106 patent/WO2002100377A1/en active Application Filing
- 2002-06-07 BR BR0210261-7A patent/BR0210261A/pt not_active IP Right Cessation
- 2002-06-07 KR KR1020097015053A patent/KR20090085162A/ko not_active Application Discontinuation
- 2002-06-07 PL PL02367883A patent/PL367883A1/xx not_active Application Discontinuation
- 2002-06-07 AU AU2002309429A patent/AU2002309429B2/en not_active Ceased
-
2003
- 2003-11-20 ZA ZA200309048A patent/ZA200309048B/en unknown
- 2003-12-05 NO NO20035438A patent/NO20035438L/no not_active Application Discontinuation
-
2008
- 2008-02-19 US US12/033,646 patent/US20080145417A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL367883A1 (en) | 2005-03-07 |
EP1401398A1 (en) | 2004-03-31 |
JP2005508865A (ja) | 2005-04-07 |
KR20040007644A (ko) | 2004-01-24 |
EA200400007A1 (ru) | 2004-04-29 |
US20080145417A1 (en) | 2008-06-19 |
NO20035438L (no) | 2004-02-05 |
MXPA03011314A (es) | 2004-12-06 |
EA008409B1 (ru) | 2007-04-27 |
CN1531420A (zh) | 2004-09-22 |
SE0102036D0 (sv) | 2001-06-08 |
CZ20033332A3 (cs) | 2004-12-15 |
ZA200309048B (en) | 2004-11-22 |
HUP0400200A2 (hu) | 2004-06-28 |
CN1286451C (zh) | 2006-11-29 |
NZ529623A (en) | 2008-04-30 |
IL158898A0 (en) | 2004-05-12 |
AU2002309429B2 (en) | 2007-08-09 |
US20040220205A1 (en) | 2004-11-04 |
CA2449571A1 (en) | 2002-12-19 |
KR20090085162A (ko) | 2009-08-06 |
WO2002100377A1 (en) | 2002-12-19 |
HUP0400200A3 (en) | 2008-03-28 |
NO20035438D0 (no) | 2003-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0210261A (pt) | Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes | |
ES2156028T3 (es) | Composiciones que contienen tetrahidrolipstatina | |
MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
UY26139A1 (es) | Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos | |
HUP9902076A2 (hu) | Szexuális rendellenességek kezelésére alkalmas intranazális készítmény | |
MXPA03005464A (es) | Agentes antivirales. | |
HUP0101268A2 (hu) | A női nemi diszfunkció kezelésére alkalmas gyógyszerkészítmények | |
GEP20053510B (en) | Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
AR053680A1 (es) | Composicion | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
IL159843A0 (en) | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
MY143549A (en) | Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases | |
AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
PT1173181E (pt) | Composicao compreendendo os inibidores da fosfodiesterase para tratar disfuncoes sexuais | |
WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
HUP0402358A2 (hu) | Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására | |
HRP20020238A2 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
HUP0402062A2 (hu) | Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények | |
EA200400691A1 (ru) | Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |